In this article, we will discuss Ixabepilone (Dosage Overview). So, let’s get started.
Ixabepilone is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting.
Ixabepilone is indicated as monotherapy for the treatment of metastatic or locally
advanced breast cancer in patients whose tumors are resistant or refractory to
anthracyclines, taxanes, and capecitabine.
General Dosing Information
The recommended dosage of Ixabepilone is 40 mg/m² administered intravenously over 3 hours every 3 weeks. Doses for patients with body surface area (BSA) greater than 2.2 m² should be calculated based on 2.2 m².